Medicilon Supports Partner Jemincare in Securing Clinical Approval for JM045 Sustained-Release Microspheres
2024-12-03 Recently, JM045 sustained-release microspheres, independently developed by the Institute of Innovative Pharmaceuticals under Jemincare Pharmaceutical Group, received clinical trial approval. Medicilon, as a trusted partner, provided pharmacokinetic studies and GLP-compliant safety evaluations, playing an instrumental role in advancing the drug development process. JM045: A New Hope for Prostate Cancer Patients JM045 is a gonadotropin-releasing hormone (GnRH) analog […]
Large Animal Models: Essential Tools in Disease Research
2024-12-02 Compared to rodents and non-human primates, large animal models such as dogs and miniature pigs offer unique advantages. They provide a balance between genetic, physiological, and structural similarities to humans, while maintaining relatively low experimental costs, making them invaluable in research and medical applications. These models are particularly effective in studying cardiovascular, neurological, dermatological, […]
PDXO Model: A Significant Advancement in Precision Oncology
2024-12-02 Patient-Derived Xenograft Organoids (PDXOs) are 3D organoid models derived from patient-derived xenograft (PDX) tumor tissues. Constructed using methods similar to those employed for patient-derived organoids (PDOs), PDXOs replicate the genetic, molecular, and structural features of the original tumors with exceptional accuracy. These models surpass traditional 2D cell cultures by preserving the complex internal architecture […]
Medicilon Boston’s Second R&D Center Grandly Sets Sail
2024-11-19 On November 15th, Medicilon proudly unveiled its second R&D center in Boston, a milestone that reinforces its commitment to global drug innovation and its strategic expansion into international markets. This achievement elevates Medicilon’s position as a competitive force in the pharmaceutical landscape while highlighting its dedication to quality and collaboration. The launch event brought […]
Did You Know That Medicilon Can Handle DMPK Studies?
2024-10-22 Medicilon Preclinical Pharmacokinetics Department has many professional scientists with rich theoretical knowledge and experimental experience for experimental design, implementation, bioanalysis and data analysis. Our Pharmacokinetics Lab has passed the NMPA GLP certification. Following the guiding principles of ICH, NMPA and FDA . The lab offers in vivo and in vitro pharmacokinetic tests according to […]
Medicilon Supports Jemincare’s JMX-2002 Liposome Injection Clinical Trial Approval
2024-12-09 Shanghai, China – October 16, 2024 – Medicilon is pleased to announce that its long-term partner, Jemincare Group Co., Ltd. (“Jemincare”), has received clinical trial approval from the China National Medical Products Administration (NMPA) for its innovative liposome injection drug, JMX-2002, for the treatment of solid tumors, including non-small cell lung cancer and breast cancer. […]
Medicilon Expands Global Presence with Official Opening of Second R&D Center in Massachusetts
2024-08-29 In August 2024, Medicilon USA Corp (Medicilon)officially commenced operations at its second R&D center in Massachusetts, USA. Research at the new facility will focus on animal models for PK/PD and toxicology studies. This milestone heralds Medicilon’s continued global business expansion. Medicilon’s U.S. R&D Center The Lexington, MA location was chosen to enhance synergy and […]
Medicilon has appointed Dr. Qingcong Lin as President of Medicilon USA Corp., further deepening the global strategic layout
2024-03-11 Medicilon, a one-stop pharmaceutical preclinical research and development CRO can simultaneously meet Chinese and American drug discovery and development needs (including GLP standards) promptly and efficiently with fast initiation times. Over the past 20 years, Medicilon has been involved in the development of 421 new drug and generic drug projects that have obtained IND […]
Medicilon 20th Anniversary – Keep pace with the times in innovation, thanks for having you
2024-02-28 In 2024, Medicilon will celebrate its 20th anniversary. At the time of departure, Medicilon shouldered the dream of China’s new drug research and development, took root in Zhangjiang, Shanghai, and embarked on a long journey to pursue the dream. During the past 20 years, Medicilon has transformed into a leading one-stop biopharmaceutical preclinical R&D […]
Medicilon’s GLP-1 New Drug R&D Service
2023-06-12 Type 2 diabetes is a progressive disease. The disease course is primarily characterized by a decline in β-cell function and worsening of insulin resistance. Therefore, various antidiabetic agents are under research and development. The hypoglycemic strategy has also shifted from “sugar control” to both “sugar control” and “heart protection”. GLP-1R agonists can improve left […]
